In 2018, advances in the treatment of gout flares came in the form of a new nurse-led management approach to serum urate lowering and evidence that allopurinol might have a better cardiovascular safety profile than febuxostat. However, are IL-1β blockers such as canakinumab the future of care for patients with gout?
Subscribe to Journal
Get full journal access for 1 year
only $17.75 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Rai, S. et al. Key barriers to gout care: a systematic review and thematic synthesis of qualitative studies. Rheumatology 57, 1282–1292 (2018).
Doherty, M. et al. Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial. Lancet 392, 1403–1412 (2018).
White, W. et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N. Engl. J. Med. 378, 1200–1210 (2018).
Solomon, D. et al. Relationship of interleukin-1β blockade with incident gout and serum uric acid levels: exploratory analysis of a randomized controlled trial. Ann. Intern. Med. 169, 535–542 (2018).
Zhu, Y., Pandya, B. & Choi, H. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007–2008. Am. J. Med. 125, 679–687 (2012).
Stamp, L., Day, R. & Yun, J. Allopurinol hypersensitivity: investigating the cause and minimizing the risk. Nat. Rev. Rheumatol. 12, 235–242 (2016).
Schlesinger, N. et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double blind trials and their initial extensions. Ann. Rhem. Dis. 71, 1839–1848 (2012).
Schlesinger, N. et al. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. Ann. Rheum. Dis. 70, 1264–1271 (2011).
Ridker, P. et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 377, 1119–1131 (2017).
Stamp, L. et al. Serum urate as surrogate endpoint for flares in people with gout: a systematic review and meta-regression analysis. Semin. Arthritis Rheum. 48, 293–301 (2018).
L. S. declares that she has received speaker fees from Amgen and is currently a co-investigator on a clinical trial (ACTRN12615001219572) of intensive urate-lowering therapy (funded by the Health Research Council of New Zealand). N.D. declares that she has received speaking fees from AbbVie, Horizon, Janssen and Pfizer, consulting fees from Hengrui, Horizon and Kowa, research funding from Amgen and AstraZeneca and is currently principal investigator on a clinical trial (ACTRN12615001219572) of intensive urate-lowering therapy (funded by the Health Research Council of New Zealand). N.D. also declares that within the past 5 years she has been principal investigator on a clinical trial of febuxostat (NCT01078389) in early gout and has received consulting or speaking fees from Menarini, Takeda and Teijin.
About this article
Cite this article
Stamp, L.K., Dalbeth, N. Prevention and treatment of gout. Nat Rev Rheumatol 15, 68–70 (2019). https://doi.org/10.1038/s41584-018-0149-7